Ultragenyx Pharmaceutical Inc

자세한 내용은 Ultragenyx Pharmaceutical Inc 회사

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

회사 정보

종목 코드 RARE

회사 이름Ultragenyx Pharmaceutical Inc

상장일Jan 31, 2014

설립일2011

CEODr. Emil D. Kakkis, M.D., Ph.D.

직원 수1294

유형Ordinary Share

회계 연도 종료Jan 31

주소60 Leveroni Ct

도시NOVATO

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호94949

전화14154838800

웹사이트https://www.ultragenyx.com/

종목 코드 RARE

상장일Jan 31, 2014

설립일2011

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

Dr. Amrit Ray, M.D.

Independent Director

18.02K

+46.74%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

15.69K

-83.00%

Mr. John R. Pinion, II

Chief Quality Officer, Executive Vice President - Translational Sciences

--

Dr. Deborah L. Dunsire, M.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

사업별USD

이름

수익

비율

Crysvita

55.08M

39.54%

Crysvita royalty revenue

47.78M

34.31%

Dojolvi

17.01M

12.21%

Evkeeza

11.03M

7.92%

Mepsevii

8.39M

6.02%

지역별USD

이름

수익

비율

North America

57.79M

41.49%

Latin America

54.89M

39.40%

Europe

23.33M

16.75%

Japan

3.29M

2.36%

사업별

지역별

사업별USD

이름

수익

비율

Crysvita

55.08M

39.54%

Crysvita royalty revenue

47.78M

34.31%

Dojolvi

17.01M

12.21%

Evkeeza

11.03M

7.92%

Mepsevii

8.39M

6.02%

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

10.55%

BlackRock Institutional Trust Company, N.A.

5.20%

Sands Capital Management, LLC

4.40%

T. Rowe Price Associates, Inc.

3.32%

Kakkis (Emil D)

2.85%

Other

73.68%

주주

비율

The Vanguard Group, Inc.

10.55%

BlackRock Institutional Trust Company, N.A.

5.20%

Sands Capital Management, LLC

4.40%

T. Rowe Price Associates, Inc.

3.32%

Kakkis (Emil D)

2.85%

Other

73.68%

주주 유형

주주

비율

Investment Advisor/Hedge Fund

44.96%

Investment Advisor

27.79%

Hedge Fund

21.16%

Individual Investor

3.56%

Research Firm

1.72%

Sovereign Wealth Fund

1.02%

Private Equity

0.70%

Pension Fund

0.65%

Bank and Trust

0.28%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

627

96.81M

102.40%

-2.03M

2025Q1

652

96.83M

102.45%

-3.19M

2024Q4

645

94.29M

102.32%

-4.54M

2024Q3

633

93.51M

101.49%

-6.93M

2024Q2

618

95.17M

101.90%

+3.05M

2024Q1

605

86.17M

101.67%

-4.74M

2023Q4

588

86.44M

105.27%

+5.64M

2023Q3

574

75.90M

106.07%

-3.60M

2023Q2

591

75.05M

105.07%

-3.13M

2023Q1

609

74.12M

105.56%

-2.85M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

9.98M

10.55%

-38.64K

-0.39%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.91M

5.2%

-49.62K

-1.00%

Mar 31, 2025

Sands Capital Management, LLC

4.16M

4.4%

-134.44K

-3.13%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.14M

3.32%

+698.80K

+28.65%

Mar 31, 2025

Kakkis (Emil D)

2.69M

2.85%

-31.78K

-1.17%

Mar 07, 2025

State Street Global Advisors (US)

2.62M

2.77%

-104.13K

-3.82%

Mar 31, 2025

Wellington Management Company, LLP

2.45M

2.59%

-8.04K

-0.33%

Mar 31, 2025

ClearBridge Investments, LLC

2.26M

2.39%

-62.50K

-2.69%

Mar 31, 2025

Adage Capital Management, L.P.

2.15M

2.27%

+965.92K

+81.64%

Mar 31, 2025

Federated Hermes Global Investment Management Corp.

2.05M

2.17%

+3.00K

+0.15%

Mar 31, 2025

31.035USD

Ultragenyx Pharmaceutical Inc

31.035

개요

회사

금융